Targeting TAO Kinases Using a New Inhibitor Compound Delays Mitosis and Induces Mitotic Cell Death in Centrosome

Chuay-Yeng Koo1, Caterina Giacomini1, Marta Reyes-Corral1

  • 1King's College London, School of Cancer Sciences, New Hunt's House, Guy's Campus, Great Maze Pond, London, United Kingdom.

Insights

Inhibiting Thousand-and-one amino acid kinases (TAOK) 1 and 2 selectively targets cancer cells with supernumerary centrosomes, inducing mitotic catastrophe and cell death while sparing normal cells.

Area of Science:

  • Cell Biology
  • Cancer Biology
  • Biochemistry

Background:

  • Thousand-and-one amino acid kinases (TAOK) 1 and 2 are crucial for mitotic progression, influencing cell rounding and spindle positioning.
  • Supernumerary centrosomes are prevalent in breast cancer tissues, often clustered to avoid multipolar mitoses and cell death.

Purpose of the Study:

  • To characterize a novel compound that selectively inhibits TAOK1 and TAOK2.
  • To investigate the therapeutic potential of TAOK inhibition in breast cancer models with amplified centrosomes.

Main Methods:

  • Characterization of an ATP-competitive TAOK inhibitor with high selectivity and low IC50 values.
  • Treatment of breast cancer cell lines (SKBR3, BT549) and normal breast cells (MCF-10A) with the TAOK inhibitor.
  • Assessment of mitotic progression, centrosome amplification, spindle multipolarity, cell death, and cell growth.

Main Results:

  • TAOK inhibition in cancer cells increased mitotic populations, centrosome amplification, and multipolar spindles, leading to cell death and inhibited growth.
  • Normal breast cells showed less dependence on TAOK activity, completing mitosis and proliferating despite inhibitor presence.
  • Live cell imaging confirmed prolonged mitosis, increased cell death, and reduced mitotic exit in TAOK-inhibited cancer cells.

Conclusions:

  • TAOK inhibition selectively induces mitotic catastrophe and cell death in centrosome-amplified cancer cells.
  • TAOK proteins represent promising therapeutic targets for breast cancer treatment, particularly in tumors with supernumerary centrosomes.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.7K